Global Cancer Antibody Drug Conjugate Market USD 30 Billion Opportunity 2028

Global Cancer Antibody Drug Conjugate Market Analysis by County:

US, Europe, Japan, China, South Korea, India, Australia, Taiwan, Canada

Global Cancer Antibody Drug Conjugate Market by Indication:

Breast Cancer, Lymphoma, Leukemia, Multiple Myeloma, Gastric Cancer, Lung Cancer

Antibody-drug conjugates are the novel class of drugs that deliver the chemotherapeutic drug directly to the cancer cell. These antibody-drug conjugates when administered intravenously, bind directly to the target cell, resulting in cell death. Owing to their high specificity and target ability towards the cancer cell and ability to overcome the limitations of conventional chemotherapeutic drugs, these drug class has gained significant interest from the pharmaceutical sector in the last few years. As of now, there are 18 antibody-drug conjugates that have been approved globally for the management of a wide range of cancers including hematological malignancies, solid tumors, and other cancers.

The encouraging response of antibody-drug conjugate in the global market has increased the competition among pharmaceutical companies. The biotechnology sector is continuously investing in research and development activities related to antibody-drug conjugate for new product launches in the market. Recently, Ambrx Pharma announced that it received a “Study May Proceed” letter from the US FDA related to an Investigational New Drug (IND) application for ARX305, an antibody-drug conjugate (ADC) designed to target CD70 to treat a broad range of solid and hematologic tumors such as renal cell carcinoma. ARX305 is the third ADC developed by Ambrx on its proprietary Engineered Precision Biologics platform that has received IND clearance. Apart from this, Heidelberg Pharma announced that the first patient has been dosed with HDP-101 in Phase I/IIa study. The open-label, multi-center Phase I/IIa study will evaluate HDP-101, a BCMA antibody-Amanitin conjugate, for the treatment of relapsed or refractory multiple myeloma. The continuous efforts by the companies suggest a promising future of antibody-drug conjugates in the coming years.

Although antibody-drug conjugates have shown promising results, their market is mainly restricted by their high cost. However, the patent expiry of drugs opens opportunities for the development of cost-effective biosimilars which increases the bioavailability. Ujvira developed by Zydus Cadila is the only biosimilar approved. Ujvira is a biosimilar to Trastuzumab Emtansine and is indicated for treating both Early and Advanced HER2-positive breast cancer. By 2030, patents of other drugs will also expire in regions like the US and Europe, which will increase the competition among pharmaceutical sectors for the development of biosimilars.

The global antibody-drug conjugate market is highly crowded and the major players in the market include Roche, Seagen, Takeda Pharmaceutical, Gilead Sciences, GlaxoSmithKline, Takeda, Astellas Pharmaceutical, ADC Therapeutics, Pfizer, Daiichi Sankyo, and Immunogen. New product launch, development, commercialization, and mergers and acquisitions are key strategies used by market players to maintain their position in the market. Recently in 2022, Adecentrx Therapeutics and AvantGen entered into a three-year, multi-target partnership for the discovery of antibodies to be developed into novel ADC therapeutic candidates.

As per our report findings, the global antibody-drug conjugate market is expected to surpass US$ 28 Billion by 2028 which is mainly attributed to an increase in the prevalence of cancer and the high demand for targeted cancer drugs. Further increasing preclinical research programs, an increase in the number of clinical trials for new cancer therapeutics, a growing emphasis on new drug discovery and development by pharmaceutical companies, and the emergence of advanced antibody therapies are some of the other major factors driving the global antibody-drug conjugate market revenue growth significantly. Apart from this, rising government initiatives, increasing awareness among the population, and the development of favorable reimbursement policies are also boosting the growth of the market during the forecast period.

The report global antibody-drug conjugate provides a comprehensive analysis on the approved drugs patent, price, and sales insight 2020 Till 2028 and ongoing clinical trials assessment by status, phase, and region. The report also provides insights into future market opportunities and regional insights.

Source: Biospace